COMPANY PROFILE

NOVIGENIX

Swiss molecular diagnostics company leveraging the host immune response and machine learning for early detection of cancer

Epalinges, SwitzerlandFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About NOVIGENIX

Novigenix is a pioneering precision medicine company specializing in Immuno Transcriptomics, a cutting-edge field that analyzes the immune system's response to detect diseases early and tailor treatments to individual patients. Operating in the biotechnology sector, Novigenix serves healthcare providers, researchers, and pharmaceutical companies. The company generates revenue through the development and commercialization of biomarker solutions that support therapeutic decision-making and improve patient outcomes. By focusing on the interaction between tumors and the host immune system, Novigenix aims to revolutionize cancer detection and treatment, ultimately enhancing health outcomes.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Epalinges, Switzerland
Employees: 19
Open positions: None listed
Dealroom signal: 63.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Predictive Analytics, Biotechnology, Oncology, Core AI, Arts & Culture, Biotech and Pharma, AI Applications
Technology: Artificial Intelligence, Deep Tech, Machine Learning
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANT✓Other financing	Mar 2025	$2M	—	Undisclosed	↗
SERIES B✓Equity / VC	Nov 2022	$20M	$80M	Undisclosed	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

NOVIGENIX website traffic

Latest recorded traffic for NOVIGENIX is 1.3K monthly website visits, up 85.7% over the last three months. NOVIGENIX's team grew 11.8% over the past year.

Latest monthly visits1.3K 3-month web change+85.7% 1-year team growth+11.8%

Monthly website visitsOct 2018–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OMOnena MedicinesRevolutionary AI-optimized medicines delivering hope where it’s needed most	Allschwil, Switzerland	Operational	9	$3.5M	$14M
INInSpheroPerfecting 3D cell technology for more physiologically relevant in vitro insights	Schlieren, Switzerland	Operational
TTTOLREMO therapeuticsFocused on the discovery and development of small molecules to prevent resistance in cancer therapy	Basel, Switzerland	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational
BIBioXplorDeveloping a computational network pharmacology platform to match optimal drug combinations to the right patients	Dublin, Ireland	Operational
ONOncoImmunityDeveloping bioinformatics software that has the ability to empower precision cancer immunotherapy	Oslo, Norway	Acquired
PEPepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets	Jerusalem, Israel	Operational
ELEpigene LabsHelping cancer researchers develop new treatments and drugs by providing them with data-driven insights	Paris, France	Operational